Sign up USA
Proactive Investors - Run By Investors For Investors

Pre-clinical data on liver disease candidate sends Ocera Therapeutics shares higher

The data will be given in what's called a poster presentation in the Netherlands.
Pre-clinical data on liver disease candidate sends Ocera Therapeutics shares higher
The candidate showed encouraging results on non-alcoholic fatty liver disease

Shares in Ocera Therapeutics Inc (NASDAQ:OCRX) raced up almost 20% as it reported positive pre-clinical data on its candidate OCR-002 ability to deal with non-alcoholic fatty liver disease (NAFLD) .

Shares in the biotech company gained 19.33% to $1.42 each.

The data will be given in what's called a poster presentation in the Netherlands.

The study investigated the effect of OCR-002 in a rat with the disease in which animals were fed a High Fat and High Cholesterol (HFHC) diet for up to 16 weeks.

NAFLD rats treated with OCR-002 showed significant reduction in the progression of fibrosis compared to untreated NAFLD animals and OCR-002 substantially reduced the liver/body weight ratio, the hepatic lipid content, and hepatic collagen.

“We are again excited to see evidence of OCR-002’s ability to target ammonia in hyperammonemia-related indications that in turn drives clinical improvement,” said Stan Bukofzer, Ocera’s chief medical officer.

Giles_55af4ddca6481.jpg


Register here to be notified of future OCRX Company articles
View full OCRX profile

Ocera Therapeutics Inc Timeline

Related Articles

shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Cynata-CEO-Dr-Ross-Macdonald-presenting-Syd-Mar-2017.jpg
March 16 2017
Dr Ross Macdonald talked stemcell research with investors.
Stem Cells
March 30 2017
WideCells is aiming to be a major supporting player through its development of a stem cell storage business and, having only listed in London last July, its newsflow so far looks to be pointing the way
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use